Schlezinger Jennifer J, Bello Anila, Mangano Kelsey M, Biswas Kushal, Patel Paridhiben P, Pennoyer Emily H, Wolever Thomas M S, Heiger-Bernays Wendy J, Bello Dhimiter
Department of Environmental Health, Boston University School of Public Health, Boston, MA, 02118, USA.
Department of Public Health, Zuckerberg College of Health Sciences, University of Massachusetts, Lowell, MA, USA.
Environ Health. 2025 Mar 15;24(1):10. doi: 10.1186/s12940-025-01165-8.
Extensive use of per- and polyfluoroalkyl substances (PFAS) has resulted in their ubiquitous presence in human blood. PFAS exposures have been associated with multiple adverse human health effects. Biomonitoring studies have focused on long-chain PFASs, but these are being replaced by short-chain PFASs or with alternate PFAS chemistries (or replacement chemistries such as GenX), resulting in changes in human exposures with time. Here, we take advantage of serum samples collected as part of a clinical trial testing the efficacy of a dietary fiber intervention to reduce serum cholesterol to investigate exposure to PFASs in Canadian participants. Serum samples were collected from 72 participants (adult males with elevated cholesterol) in 2019-2020 at baseline and after 4 weeks of the intervention and were analyzed for 17 PFASs. The highest geometric mean serum concentrations of PFAS measured at baseline corresponded to PFOSA (7.1 ng/ml), PFOS (4.2, ng/ml), PFOA (1.8 ng/ml) and PFHxS (1.3 ng/ml). Four long-chain PFASs (PFOA, PFOS, PFOSA and PFHxS) and two short-chain PFASs (PFBA, PFHxA) were detected in 100% of participants. GenX was detected in 71% of participants. Analyses of associations between serum-PFAS concentrations and biomarkers of adverse health outcomes showed the PFBA, PFHxA, PFDA and PFOSA were associated with higher serum gamma-glutamyl transferase concentrations but not with measures of serum-total or low-density lipoprotein cholesterol. Comparison of PFAS concentrations at baseline and after a 4-week follow-up showed that the total PFAS detected decreased in both the control and cholesterol intervention groups. However, the suite of long-chain PFASs of concern identified by the United States National Academies of Sciences, Engineering, and Medicine, significantly decreased only in the cholesterol intervention group. This observation suggests that a sustained dietary fiber intervention may reduce long-chain PFAS body burden, but future intervention studies need to control for PFAS exposure sources and extend the dietary supplement intake beyond 4 weeks. Overall, the results show that exposures to short-chain and replacement chemistry PFASs are common in this Canadian population.
全氟和多氟烷基物质(PFAS)的广泛使用导致其在人体血液中普遍存在。PFAS暴露与多种不良人体健康影响相关。生物监测研究主要集中在长链PFAS,但这些正被短链PFAS或其他PFAS化学物质(或替代化学物质如GenX)所取代,导致人体暴露随时间发生变化。在此,我们利用作为一项膳食纤维干预降低血清胆固醇疗效临床试验一部分所收集的血清样本,来调查加拿大参与者中PFAS的暴露情况。2019 - 2020年,从72名参与者(胆固醇升高的成年男性)中在基线期和干预4周后收集血清样本,并对17种PFAS进行分析。在基线期测得的PFAS最高几何平均血清浓度对应于全氟辛烷磺酸(PFOSA,7.1纳克/毫升)、全氟辛烷磺酸(PFOS,4.2纳克/毫升)、全氟辛酸(PFOA,1.8纳克/毫升)和全氟己烷磺酸(PFHxS, 1.3纳克/毫升)。100%的参与者检测到四种长链PFAS(PFOA、PFOS、PFOSA和PFHxS)和两种短链PFAS(PFBA、PFHxA)。71%的参与者检测到GenX。血清PFAS浓度与不良健康结局生物标志物之间的关联分析表明,PFBA、PFHxA、PFDA和PFOSA与较高的血清γ-谷氨酰转移酶浓度相关,但与血清总胆固醇或低密度脂蛋白胆固醇指标无关。基线期和4周随访后的PFAS浓度比较表明,对照组和胆固醇干预组中检测到的总PFAS均下降。然而,美国国家科学院、工程院和医学院确定的一系列令人关注的长链PFAS仅在胆固醇干预组中显著下降。这一观察结果表明,持续的膳食纤维干预可能会降低长链PFAS的身体负担,但未来的干预研究需要控制PFAS暴露源,并将膳食补充剂的摄入时间延长至4周以上。总体而言,结果表明短链和替代化学物质PFAS在该加拿大人群中的暴露很常见。